Advances in™ PTCL: Mid-Year Report from Chicago and Austria

Release Date: July 28, 2021
Expiration Date: July 28, 2022

Activity Overview

This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of peripheral T-cell lymphoma (PTCL), with a forward-looking perspective on how new and novel agents might impact clinical practice. The essentials of recent advances in treating PTCL will be presented in a multimedia format, including a series of video interviews with an expert thought leader integrated into text-based elements.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Daiichi Sankyo, Inc.

Target Audience

This educational program is directed toward medical oncologists, hematologists, pathologists, and other oncology health care professionals interested in the latest advances in PTCL. Other allied healthcare professionals, including histologists, nurse practitioners, physician assistants, and nurses involved in the treatment of patients with PTCL will also be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Explain the study design and rationale of recent clinical trials for the treatment of PTCL
• Evaluate recent efficacy and safety findings from clinical trials that have investigated emerging approaches among patients with PTCL
• Apply efficacy and safety results from trials evaluating patients with PTCL to personalize application of novel emerging agents along the disease continuum

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities.

Faculty

Steven Horwitz, MD
Associate Attending
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant/Research Support: ADC Therapeutics, Affimed, Aileron, Celgene, Daiichi Sankyo, Forty Seven, Inc., Kyowa Hakko Kirin, Millennium /Takeda, Seattle Genetics, Trillium Therapeutics, and Verastem/Secura Bio. Consultant: Acrotech Biopharma, ADC Therapeutics, Astex, C4 Therapeutics, Celgene, Janssen, Kura Oncology, Kyowa Hakko Kirin, Myeloid Therapeutics, ONO Pharmaceuticals, Seattle Genetics, Secura Bio, Shoreline Biosciences, Inc., Takeda, Trillium Therapeutics, Tubulis, Verastem, and Vividion Therapeutics.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.